Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

CLDN18 (Claudin 18)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

VENTANA CLDN18 (43-14A) Assay (2)

Claudin18.2 IHC 14G11 pharmDx

VENTANA CLDN18 (43-14A) Assay (2)

Claudin18.2 IHC 14G11 pharmDx

›

CLDN18.2 positive + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 positive + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	zolbetuximab-clzb Sensitive: A1 - Approval zolbetuximab-clzb Sensitive : A1	zolbetuximab-clzb Sensitive: A1 - Approval zolbetuximab-clzb Sensitive : A1
CLDN18.2 positive + HER-2 negative	Gastric Cancer	CLDN18.2 positive + HER-2 negative	Gastric Cancer	zolbetuximab-clzb Sensitive: A1 - Approval zolbetuximab-clzb Sensitive : A1	zolbetuximab-clzb Sensitive: A1 - Approval zolbetuximab-clzb Sensitive : A1
CLDN18.2 expression + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 expression + HER-2 negative	Gastroesophageal Junction Adenocarcinoma	zolbetuximab-clzb Sensitive: B - Late Trials zolbetuximab-clzb Sensitive : B	zolbetuximab-clzb Sensitive: B - Late Trials zolbetuximab-clzb Sensitive : B
CLDN18.2 expression + HER-2 negative	Gastric Cancer	CLDN18.2 expression + HER-2 negative	Gastric Cancer	zolbetuximab-clzb Sensitive: B - Late Trials zolbetuximab-clzb Sensitive : B	zolbetuximab-clzb Sensitive: B - Late Trials zolbetuximab-clzb Sensitive : B
CLDN18.2 expression	Gastric Cancer	CLDN18.2 expression	Gastric Cancer	EO-3021 Sensitive: B - Late Trials EO-3021 Sensitive : B	EO-3021 Sensitive: B - Late Trials EO-3021 Sensitive : B
CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	IBI-343 Sensitive: B - Late Trials IBI-343 Sensitive : B	IBI-343 Sensitive: B - Late Trials IBI-343 Sensitive : B
CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	EO-3021 Sensitive: B - Late Trials EO-3021 Sensitive : B	EO-3021 Sensitive: B - Late Trials EO-3021 Sensitive : B
CLDN18.2 expression	Esophageal Adenocarcinoma	CLDN18.2 expression	Esophageal Adenocarcinoma	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2
CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	CLDN18.2 expression	Gastroesophageal Junction Adenocarcinoma	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2
CLDN18.2 expression	Gastric Adenocarcinoma	CLDN18.2 expression	Gastric Adenocarcinoma	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2	zolbetuximab-clzb Sensitive: C2 – Inclusion Criteria zolbetuximab-clzb Sensitive : C2
CLDN18.2 positive	Gastric Cancer	CLDN18.2 positive	Gastric Cancer	CT041 Sensitive: C2 – Inclusion Criteria CT041 Sensitive : C2	CT041 Sensitive: C2 – Inclusion Criteria CT041 Sensitive : C2
CLDN18.2 positive	Pancreatic Ductal Adenocarcinoma	CLDN18.2 positive	Pancreatic Ductal Adenocarcinoma	CT041 Sensitive: C2 – Inclusion Criteria CT041 Sensitive : C2	CT041 Sensitive: C2 – Inclusion Criteria CT041 Sensitive : C2